U of M study reveals immunotherapy's potential in boosting immune systems of older individuals
MINNEAPOLIS/ST. PAUL (5/15/2024) — Published in Nature Aging, University of Minnesota Medical School researchers provided new insight into enhancing immune responses in older individuals and the potential for using immunotherapy to make older adults less vulnerable to infections.
Using preclinical models, the research team studied the impact of monoclonal anti-PD1 immunotherapy treatment — which are drugs that increase immune function — when exposed to serious infections. They found that this treatment improved survival rates because it boosted the ability of CD8+ T cells to kill harmful cells infected with a virus.
“We have unveiled a promising role for PD1 blockade in combating immunosenescence,” said Korbyn Dahlquist, a graduate student in the University of Minnesota Medical School. “This highlights the potential of addressing age-related immune dysfunction during infectious disease.”
Older individuals are at the highest risk for mortality from infections, largely due to the aging of the immune system. Exhausted T cells — which normally help protect the body from infection — accumulate during aging and contribute to a weakened immune response.
In this study, the research team tested whether checkpoint blockade therapy — which improves CD8+ T-cell responses by blocking inhibitory receptors — would also improve the immune response of older mice. However, overamplification of T-cell receptor signaling and T-cell activation can lead to excess inflammation and adverse events that have a negative impact on the response to infection.
“These results help us understand the biology of the aging immune system, but also support the use of checkpoint blockade therapy in geriatric individuals,” said Christina Camell, PhD, the study’s corresponding author.
Future research will be focused on using senolytics and checkpoint blockade therapy as a dual therapy option to improve the immune response and reduce symptoms of infections in older individuals.
Funding was provided by the National Institutes of Health [grants R00AG058800, R21AG078638, R01AG079913-01, R01AI155468, T32AG029796], the Fesler-Lampert Chair in Aging Studies, the Glenn Foundation for Medical Research/AFAR Grants for Junior Faculty, the McKnight Land-Grant Professorship, Irene Diamond Fund/AFAR Postdoctoral Transition Award, the Medical Discovery Team on the Biology of Aging, and a Longevity Impetus Grant from Norn Group.
###
About the University of Minnesota Medical School
The University of Minnesota Medical School is at the forefront of learning and discovery, transforming medical care and educating the next generation of physicians. Our graduates and faculty produce high-impact biomedical research and advance the practice of medicine. We acknowledge that the U of M Medical School is located on traditional, ancestral and contemporary lands of the Dakota and the Ojibwe, and scores of other Indigenous people, and we affirm our commitment to tribal communities and their sovereignty as we seek to improve and strengthen our relations with tribal nations. For more information about the U of M Medical School, please visit med.umn.edu.